Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings

Takeda Pharmaceutical Co Ltd's TAK Phase 3 PhALLCON trial of Iclusig (ponatinib) met its primary endpoint in newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients.
The study demonstrated that Iclusig plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease (MRD)-complete negative remission (CR) compared to imatinib.
In the trial, no new safety signals were observed.
Related: Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids.
In September, Puma Biotechnology Inc PBYI announced an agreement to license the worldwide research and development and commercial rights to Takeda's alisertib for cancer indications.
Alisertib has been tested in metastatic cancers, including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma, and acute myeloid leukemia.
Price Action: TAK shares are up 1.13% at $13.93 on the last check Thursday.
Photo Via Company